INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2009

Higher green tea extract doses improved response rates in oral premalignant lesions.

Patients with high-risk oral premalignant lesions received green tea extract (500, 750, or 1,000 mg/m2) or placebo three times daily for 12 weeks. Clinical response was 50% across extract groups (n = 28) versus 18.2% for placebo (n = 11; P = 0.09), but reached 58.8% in the two highest-dose groups combined (P = 0.03). Histologic improvement was not significantly different (P = 0.65), and while higher doses increased insomnia and nervousness, no grade 4 toxicities were seen.

Study type
Randomized placebo-controlled trial
Who was studied
39 patients with high-risk oral premalignant lesions
What was measured
Clinical and histologic response of oral premalignant lesions

THE PAPER

Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions.

Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, El-Naggar AK, Wistuba I, Culotta KS, Mao L, Gillenwater A, Sagesaka YM, Hong WK, Papadimitrakopoulou V. Cancer Prev Res (Phila), 2009.

PubMed 19892663 ↗DOI 10.1158/1940-6207.CAPR-09-0121 ↗

Cancer

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.